OncoTherapy Science (TSE:4564) Research & Development: 円534.9 Mil (TTM As of Mar. 2026)


TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.03
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Research & Development?

OncoTherapy Science TSE:4564 +5.00% 50 Research & Development is 円534.9 Mil as of Mar. 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円17.03 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OncoTherapy Science's Research & Development for the six months ended in Mar. 2026 was 円248.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円534.9 Mil.

OncoTherapy Science  (TSE:4564) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OncoTherapy Science Research & Development Related Terms

OncoTherapy Science Research & Development Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Research & Development Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,730.27 716.46 678.05 491.11 534.94

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 272.29 262.38 228.74 286.98 247.96
TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円534.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円534.9 Mil mean?
OncoTherapy Science (TSE:4564) has a Research & Development of 円534.9 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's Research & Development too high?
OncoTherapy Science's current Research & Development is 円534.9 Mil. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Research & Development compare to VRTX and REGN?
OncoTherapy Science's Research & Development of 円534.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Research & Development is 円534.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.03, compared to a current price of 円21.00 — trading 23.3% above its estimated fair value. The current Research & Development is 円534.9 Mil. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Research & Development is 円534.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 23.3% above its estimated GF Value™ of 円17.03. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • Research & Development: 円534.9 Mil
  • GF Value™: 円17.03 vs. price of 円21.00 (23.3% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.03
GF Value